The assembly of neuronal networks during development requires tightly controlled cell-cell interactions. Multiple cell surface receptors that control axon guidance and synapse maturation have been identified. However, the signaling mechanisms downstream of these receptors have remained unclear. Receptor signals might be transmitted through dedicated signaling lines defined by specific effector proteins. Alternatively, a single cell surface receptor might couple to multiple effectors with overlapping functions. We identified the neuronal RacGAP a2-chimaerin as an effector for the receptor tyrosine kinase EphA4. a2-Chimaerin interacts with activated EphA4 and is required for ephrin-induced growth cone collapse in cortical neurons. a2-Chimaerin mutant mice exhibit a rabbit-like hopping gait with synchronous hindlimb movements that phenocopies mice lacking EphA4 kinase activity. Anatomical and functional analyses of corticospinal and spinal interneuron projections reveal that loss of a2-chimaerin results in impairment of EphA4 signaling in vivo. These findings identify a2-chimaerin as an indispensable effector for EphA4 in cortical and spinal motor circuits.
INTRODUCTION
Cell surface recognition and signaling receptors enable developing neurons to detect cues in their environment and respond to these cues by alterations in migration, growth, and cellular differentiation. Work over the past 20 years has led to the identification of an array of surface receptors and ligands that underlie specific axonal guidance decisions, but the downstream signaling mechanisms are only poorly understood (Dickson, 2002; Raper, 2000; Tessier-Lavigne and Goodman, 1996; Yu and Bargmann, 2001 ). Several activated receptors couple to Rho GTPase-activating proteins (GAPs) and guanosine nucleotide exchange factors (GEFs) that drive local inactivation or activation of the Rho family of GTPases, respectively, and thereby ultimately control cytoskeletal and membrane dynamics in growth cones (Luo, 2002; Shamah et al., 2001; Wong et al., 2001; Yang and Bashaw, 2006) . The logic by which GAP and GEF effector proteins transduce surface receptor signals has remained unclear. Analysis of the human genome sequence predicts 69 GEFs and up to 70 GAPs for Rho family GTPases; however, the biological relevance of this molecular diversity is not well understood (Peck et al., 2002; Schiller, 2006; Tcherkezian and Lamarche-Vane, 2007) . Biochemical studies suggest that a single surface receptor can interact with multiple GAPs and GEFs and that a single GAP or GEF can interact with multiple different surface receptors. This poses the question whether there are dedicated Rho family GTPase regulators that are absolutely required for one class of receptors in vivo or whether receptor signals are transduced through multiple GAPs and GEFs that act through partially redundant pathways and are associated with many different surface receptors.
One particularly well-studied example of a neuronal surface receptor is the EphA4-receptor tyrosine kinase (Pasquale, 2005) . Genetic studies in mice have implicated EphA4 in controlling multiple axonal guidance steps, most prominently in the locomotor circuits (Kiehn, 2006) . Mice lacking EphA4 exhibit a pronounced locomotor defect characterized by synchronous movement of their hindlimbs, which results in a rabbit-like hopping gait (Dottori et al., 1998; Kullander et al., 2003) . This behavioral phenotype is thought to result from aberrant midline crossing of corticospinal tract (CST) and spinal interneuron axons and inappropriate innervation of contralateral spinal cord hemisegments (Dottori et al., 1998; Kullander et al., 2001b; Yokoyama et al., 2001) .
In a search for mediators of Eph-receptor forward signaling, multiple Rho family GAPs and GEFs have been isolated, including the EphA4 effectors ephexin-1, Vsm, and Vav-2/-3 Irie and Yamaguchi, 2002; Ogita et al., 2003; Penzes et al., 2003; Shamah et al., 2001; Tanaka et al., 2004) . How these multiple EphA4 effectors cooperate in vivo has remained unclear. While knockout studies for ephexin-1 and Vav-2/-3 support important functions in axonal guidance, neither one of these knockout models reproduces the EphA4 mutant phenotype Sahin et al., 2005) . This could be explained if EphA4 downstream signaling is mediated through a complex signaling network composed of multiple effectors with redundant functions. Alternatively, EphA4 signaling in the locomotor circuits may depend on highly dedicated effector proteins that have not yet been identified.
One new family of candidate effector proteins for axonal guidance is the chimaerins, which we recovered in a microarray screen for genes involved in axonal growth and synapse formation (Diaz et al., 2002) . Two a-chimaerin isoforms (a1 and a2) expressed from a single genomic locus under the control of two promoters were originally identified by Lim and colleagues (Dong et al., 1995; Hall et al., 1990 Hall et al., , 1993 . Both isoforms share identical diacylglycerol-binding (C1) and RacGAP domains, but a2-chimaerin contains an additional Src-homology-2 (SH2) domain ( Figure 1A ) (Hall et al., , 1993 . In a crystal structure of the highly homologous b2-chimaerin, this SH2 domain covers the C1 and GAP domains, suggesting that opening of this closed conformation might be required for access to binding partners (Canagarajah et al., 2004) . The GAP domain of a2-chimaerin downregulates Rac activity in vitro and in transfected cells Hall et al., 2001) . Furthermore, overexpression and knockdown studies suggest that a-chimaerins inactivate Rac and that the a1-chimaerin isoform contributes to dendritic retraction events in cultured neurons (Buttery et al., 2006; Leskow et al., 2006; Van de Ven et al., 2005) . In this study, we searched for novel a2-chimaerin interaction partners and identified activated Eph receptors. We characterized the behavioral, anatomical, and functional abnormalities in the locomotor circuits of a2-chimaerin-deficient mice and discovered that they closely resemble defects of mice lacking EphA4 kinasedependent functions. These findings suggest that ablation of a single cytoplasmic effector protein results in a severe but rather selective loss of EphA4-receptor function.
RESULTS

a2-Chimaerin Is an Eph Effector
We hypothesized that a2-chimaerin might interact via its SH2 domain with tyrosine kinase receptors. To identify such receptors, we performed affinity chromatography of solubilized membrane proteins on an immobilized recombinant protein of the a2-chimaerin SH2 domain fused to gluthathione S-transferase (GST). Anti-phosphotyrosine antibodies revealed several candidate binding proteins. Based on its size and reactivity with anti-EphA4 antibodies, one of these proteins was identified as EphA4 ( Figure 1B) . To examine the selectivity of this biochemical interaction, we performed pull-down assays with lysates from HEK293T cells overexpressing full-length EphA4, EphB1, EphB2, TrkA, neurexin-1b, or SHPS1. In this assay, all of the tested Eph receptors were efficiently recovered on GST-SH2 beads, but not on beads containing a GST control protein ( Figure 1C and data not shown). (A) Schematic diagram of a1-and a2-chimaerin isoform domain structure. Both isoforms share identical diacylglycerol-binding C1 and GTPase-activating protein (GAP) domains; a2-chimaerin contains an additional unique N-terminal Src-homology-2 (SH2). (B) Pull-down assays from cortical lysates with GST control beads (GST), or GST-SH2 beads carrying the purified recombinant a2-chimaerin SH2 domain (SH2). Input lysates (input) and bound proteins (GST or SH2) were probed in western blots for EphA4 and TrkA. (C) EphA4, EphB1, or TrkA were overexpressed in HEK293T cells and incubated with GST control beads or GST-SH2 beads. Blots show an aliquot of the total cell lysate (input) or proteins bound to GST beads or GST-SH2 beads probed with anti-EphA4 (A4), antiEphB1 (B1), anti-TrkA, or anti-phosphotyrosine antibodies (p-Tyr). (D) GST pull-down with GST control beads or GST-SH2 beads from HEK293T cell lysates expressing full-length wild-type EphA4 (A4), EphA4-V635M (KD), EphA4-Y596E/Y602E (EE), or EphA4-Y596E/Y602E/V635M (EE/KD). Bound proteins were probed with anti-EphA4 antibodies, and an aliquot of the cell lysate was probed with anti-EphA4 and anti-phosphotyrosine antibodies (p-Tyr). (E) HEK293T cells overexpressing full-length HA-tagged a2-chimaerin or a1-chimaerin were incubated with beads carrying purified recombinant maltose-binding protein (MBP), MBP fused to the intracellular domain of EphA4 (A4), MBP fused to the intracellular domain of EphA4 treated with l-phosphatase (A4-l), MBP fused to the intracellular domain of EphA4-Y596E/Y602E, or MBP fused to a kinase-dead mutant (V635M) of the intracellular domain of EphA4 (A4-KD). Bound proteins were detected with anti-HA antibodies. (F) a2-Chimaerin was immunoprecipitated from lysates of control HEK293 cells or cells expressing a2-chimaerin, a2-chimaerin and EphA4, or a2-chimaerin and kinase-dead EphA4 (A4-KD). Immunoprecipitates were probed with antibodies to phosphotyrosine antibodies (p-Tyr) or a2-chimaerin (a2). Expression of EphA4 in cell lysates was confirmed with anti-EphA4 antibodies (EphA4).
No significant binding was observed for TrkA, another tyrosine kinase receptor, or the transmembrane adhesion molecules neurexin-1b and SHPS1 ( Figure 1C and data not shown).
We next examined whether a2-chimaerin preferentially interacts with activated, tyrosine-phosphorylated EphA4 receptors. In pull-down assays with the recombinant a2-chimaerin SH2 domain as bait, no full-length kinasedead receptors were recovered (KD, V635M; Figure 1D ). In the same assay, an EphA4 mutant that maintains kinase activity but has the two juxtamembrane tyrosinephosphorylation sites mutated to glutamate (EE; Y596E/ Y602E) (Binns et al., 2000; Holland et al., 1997; Zisch et al., 2000) showed reduced interaction with the a2-chimaerin SH2 domain. Finally, binding of this doubleglutamate mutant was not altered when combined with the kinase-dead mutation (EE/KD) ( Figure 1D ). These interactions suggest that the juxtamembrane tyrosines play an important role in binding the a2-chimaerin SH2 domain to activated EphA4. Morevover, full-length a2-chimaerin bound EphA4 in a kinase-activity-dependent manner. Full-length a2-chimaerin expressed in HEK293T cells bound efficiently to beads containing the recombinant intracellular domain of the EphA4 receptor (A4) fused to maltose-binding protein (MBP) but not to an MBP control protein ( Figure 1E ). Binding was severely reduced after dephosphorylation of EphA4 with l-phosphatase (A4-l) and was not detectable for EphA4 kinase-dead receptors (A4-KD; Figure 1E ). The double-glutamate mutant showed reduced binding as compared to the wild-type EphA4. Interestingly, the SH2 domain of a2-chimaerin was not absolutely required for interaction with recombinant EphA4. a1-chimaerin, which lacks the SH2 domain, still interacted with EphA4, though this interaction was not dependent on EphA4 kinase activity. In combination, these data suggest that a2-chimaerin contains at least two binding sites for EphA4, one in the SH2 domain and one in the remainder of the protein. The second binding site appears to be accessible only once the SH2 domain engages in binding to phosphotyrosine residues in activated EphA4. Our attempts to coimmunoprecipitate a2-chimaerin and EphA4 either from brain lysates or from transfected HEK293 cells failed, suggesting that binding might be transient or show a high off-rate. However, in cotransfected HEK293 cells, we did observe EphA4-dependent tyrosine phosphorylation of a2-chimaerin, providing further evidence for functional coupling between the two proteins ( Figure 1F ). In summary, these biochemical studies identify a2-chimaerin as a signaling effector for activated Eph receptors that might be required for transduction of Ephreceptor signaling.
a2-Chimaerin Mutant Mice Exhibit Locomotor Defects
To examine the relevance of a2-chimaerin for Ephreceptor signaling, we obtained mice with a gene-trap insertion in the a-chimaerin gene. The trap insertion is located upstream of the putative a1-chimaerin promoter (Dong et al., 1995) and selectively suppresses a2-chimaerin full-length mRNA and protein levels, without detectable effect on the a1-chimaerin isoform (Figures 2A and 2B) . Heterozygous gene-trap mice did not show any overt anatomical or behavioral phenotype. Therefore, we used the lacZ reporter within the gene-trap cassette in a2-chimaerin heterozygous mice to characterize the pattern of a2-chimaerin expression (Figures 2A and 2C ). This analysis revealed widespread neuronal expression consistent with previous in situ hybridization studies (Hall et al., 1993) . In postnatal day 5 cortex, a2-chimaerin expression was detected in multiple layers, including CTIP2-positive layer V neurons, which are the source of corticospinal tract axons (Arlotta et al., 2005) (Figure 2C ). High expression was also observed in the retinal ganglion cells and dorsal root ganglia (data not shown). In the spinal cord, the lacZ reporter was detected in NeuN-positive interneuron populations, including cells in the ventromedial zone as well as presumptive motor neurons ( Figure 2C ).
Homozygous a2-chimaerin mutant mice are born at Mendelian frequencies and are viable and fertile. Overall brain architecture including the anterior commissure in a2-chimaerin mutant mice did not show any apparent defects ( Figure 3A and data not shown). However, the homozygous mutant mice exhibit a pronounced locomotor deficit during walking. While wild-type mice move their hindlimbs in alternation, a2-chimaerin mutants show synchronous hindlimb movement observed as a rabbit-like hopping-gait ( Figure 3B and Movies S1 and S2). Importantly, this behavioral defect phenocopies locomotor abnormalities observed in EphA4 mutant mice (Dottori et al., 1998; Kullander et al., 2001a) , suggesting that loss of a2-chimaerin may impair EphA4 function.
a2-Chimaerin Is Required for Ephrin-Induced Growth Cone Collapse
Repulsive EphA4-receptor signaling responses can be visualized in vitro as ephrin ligand-induced growth cone collapse. To test whether a2-chimaerin-deficient axons had lost their ability to respond to ephrins, we cultured cortical explants from the presumptive motor cortex area, which expresses high levels of EphA4 and a2-chimaerin. As observed by time-lapse imaging, basal growth rates of axons extending from wild-type and a2-chimaerin mutant explants were not significantly different over the initial 15 min of imaging (p > 0.05, t test; Figure 4C ). Application of recombinant ephrinA1-Fc fusion protein, a high-affinity ligand specific for A-class Eph receptors, induced robust growth cone collapse in wild-type axons within 30 min of application ( Figure 4A and Movie S3). In contrast, axons from a2-chimaerin mutant explants were largely resistant to ephrinA1-induced collapse (Figures 4A and 4B and Movie S4; p = 0.004, t test) . Additional measurements of growth rates 30 min after ephrinA1 application revealed that the mutant axons continued to advance in the presence of the repulsive cue ( Figure 4C ). Importantly, EphA4 staining on wild-type and mutant axons were not noticeably different ( Figure 4D ), and EphA4 protein levels in lysates of the cortical explants from wild-type and mutant mice were unchanged. Moreover, explants showed significant levels of a1-chimaerin expression, regardless of the genotype ( Figure 4E ). This suggests that the a2-chimaerin isoform is essential for the transduction of repulsive ephrin-induced signaling in motor cortex axons in vitro.
a2-Chimaerin Mutant Mice Show Aberrant Midline Crossing of Spinal Interneuron Projections
In the lumbar spinal cord, repulsive EphA4 signaling prevents inappropriate midline crossing of spinal interneuron axons, and the locomotor abnormalities in EphA4 mutant mice are attributed at least in part to aberrant innervation of the contralateral central pattern generator (CPG) (Dottori et al., 1998; Kullander et al., 2001a Kullander et al., , 2003 Yokoyama et al., 2001) . Because a2-chimaerin mutant mice exhibit similar locomotor defects as EphA4 mutants and show reduced Eph-receptor-mediated repulsion, we analyzed whether loss of a2-chimaerin causes defects in spinal interneuron pathfinding. We performed unilateral injections of rhodamine-dextran into the lumbar spinal cord segment L4 and examined retrogradely labeled axonal projections in transverse sections at L2 ( Figure 5A ). In a2-chimaerin mutant animals, we observed an increase in the number of rhodamine-positive fibers crossing the midline as compared to wild-type ( Figure 5B) . A significant increase in midline crossing was further confirmed in quantitative analysis of the label density near the midline on the contralateral side (fraction of 10 3 100 mm region of interest that is dextran positive on contralateral side: 3.7% ± 1.8% in wild-type and 33.4% ± 5.1% in a2-chimaerin mutant spinal cords, n > 12 mice per genotype, >4 consecutive sections analyzed per animal, p = 0.004, t test). In contrast, ipsilateral labeling was similar between the two genotypes (p = 0.42, t test). Despite the severe defect in midline crossing, other axonal projections in the spinal cord of a2-chimaerin mutants were apparently unperturbed. We examined the central projections of proprioceptive sensory afferents, which depend on plexinA1 signaling for axon positioning within the dorsal spinal cord (Yoshida et al., 2006) . Immunostaining with antibodies to parvalbumin, a marker of proprioceptive afferents (Arber et al., 2000) , revealed that parvalbumin-positive axons were similarly excluded from the superficial dorsal horn in wild-type and a2-chimaerin mutant spinal cords ( Figure S1 ). Therefore, a2-chimaerin is required for restricting midline crossing of interneurons in the lumbar spinal cord but not for the positioning of proprioceptive sensory afferents. To test whether EphA4 and a2-chimaerin genetically interact in restricting midline crossing of spinal interneurons, we examined single and double heterozygous EphA4 and a2-chimaerin mutant mice. While single heterozygous mutants did not show any overt phenotype, a2-chimaerin +/À ; EphA4 +/À double heterozygotes exhibited a partially (B) Images and footprints of wild-type animals display an alternating hindlimb gait, while a2 gene-trap mutants display a synchronous rabbit-like hopping gait. Direction of animal movement is from left to right. Blue represents the left forelimb, red is right forelimb, green is left hindlimb, and yellow is right hindlimb. See Movies S1 and S2 of wild-type and mutant animals, respectively. Scale bar is 1 cm. penetrant hindlimb locomotor phenotype characterized by perturbed hindlimb coordination and occasional synchronous hindlimb movements. Rhodamine dextran tracing revealed increased midline crossing of fibers as compared to the wild-type mice. A genetic interaction between EphA4 and a2-chimaerin was also observed at the level of spinal cord morphology. The dorsal funiculus in EphA4 mutant mice is broader and more shallow than in wildtype or heterozygous mutant mice (Dottori et al., 1998; Kullander et al., 2001a Kullander et al., , 2001b ). This phenotype is also observed in a2-chimaerin mutants, and a2-chimaerin +/À ; EphA4 +/À double heterozygotes show a similar though somewhat less severe defect ( Figures 5C and 5D ). These findings provide genetic evidence supporting the a2-chimaerin-EphA4 interactions observed in our biochemical studies and strongly suggest that both proteins act in a common signaling pathway in vivo.
Corticospinal Defects in a2-Chimaerin Mutant Mice
We next examined CST projections in a2-chimaerin mutant mice. The anterograde tracer biotin-dextran amine was injected into one side of the motor cortex of adult mice, and descending CST axonal projections in the spinal cord were observed 10-12 days later ( Figure 6A ). Wild-type animals exhibited strictly contralateral labeling within the dorsal funiculus and predominantly contralateral terminations within the spinal gray matter ( Figure 6B ). In a2-chimaerin mutant mice, CST axons were also restricted to the contralateral dorsal funiculus. However, there were extensive bilateral terminations within the spinal gray matter, indicating that a2-chimaerin mutant CST axons fail to respect the repulsive ephrin barrier along the midline (Figures 6B and 6C ; n = 5 animals/genotype, 4 sections/animal, p = 0.008, t test). Taken together, our anatomical studies demonstrate that a2-chimaerin mutant mice selectively phenocopy defects resulting from impaired EphA4 forward signaling in spinal and cortical motor circuits in vivo.
a2-Chimaerin Mutants Show Bilateral Hindlimb Movements in Response to Cortical Stimulation
The anatomical studies reveal inappropriate midline crossing for the axons of corticospinal motor neurons and spinal interneurons. To directly test whether the loss of bilateral segregation of these axonal pathways was responsible for the functional defects in a2-chimaerin mice, we performed extracellular microstimulation within the hindlimb representation of the motor cortex (Li and Waters, 1991) and observed hindlimb movements and muscle activation. In wild-type animals, a threshold stimulus (18.75 ± 0.75 mA, n = 4 animals) applied in motor cortex of one cortical hemisphere resulted in exclusively contralateral EMGs and hindlimb flexion ( Figure 7A ). Weak ipsilateral hindlimb responses in wild-type animals could be recruited only with supramaximal stimuli (66 ± 11 mA, n = 4 animals). In contrast, unilateral stimulation of motor cortex in a2-chimaerin mutant mice evoked exclusively bilateral EMGs and hindlimb flexion at threshold intensity (21 ± 4.02 mA, n = 4; Figures 7A and 7B ). These bilateral responses in a2-chimaerin mutant mice might result from bilateral CST projections that trigger local spinal motor circuits on both sides of the spinal cord. Alternatively, bilateral stimulus-evoked responses might be due to contralateral CST projections that activate interneurons of spinal motor circuits with aberrant bilateral connections to motor neurons. In either scenario, our data suggest that the wiring defects in spinal motor circuits are responsible for hindlimb synchrony in the a2-chimaerin mutant mice.
DISCUSSION
Our findings provide several important insights into the mechanisms of Eph-receptor signaling. We demonstrate that a2-chimaerin is a downstream effector for EphA4. Loss of a2-chimaerin results in a close phenocopy of the anatomical and locomotor defects in EphA4 knockin mice expressing a kinase-dead receptor. Biochemical and genetic evidence supports an interaction between activated EphA4 and a2-chimaerin. Jointly, these findings suggest that a2-chimaerin is a dedicated signaling effector that is essential for EphA4-receptor forward signaling in cortical and spinal motor circuits. Several lines of evidence support the conclusion that abnormalities in the a2-chimaerin mutant mice are due to an impairment of downstream signaling and not simply a lack of EphA4-receptor expression. Our biochemical studies suggest an interaction with activated EphA4 and EphA4-dependent tyrosine phosphorylation of a2-chimaerin. Moreover, EphA4 protein levels in tissue lysates and in axonal growth cones are unaltered in the a2-chimaerin mutant mice, and, most importantly, formation of the anterior commissure, which depends on EphA4 reverse signaling, is normal in a2-chimaerin mutants. Therefore, the phenocopy of the EphA4-receptor mutant in the corticospinal tract and spinal interneuron projections of a2-chimaerin mutant mice is due to the loss of an indispensable downstream signaling function of the a2-chimaerin protein.
The biochemical interactions and regulation of Rac activity by a2-chimaerin are likely to be complex. The a2-chimaerin isoform appears to exist in a closed conformation. Our data suggest that opening of this conformation can be achieved by SH2-domain-dependent binding to tyrosine-phosphorylated EphA4, which then exposes an additional a2-chimaerin-EphA4 interaction site. This opening might also be required to make the Rac-GAP domain available for Rac binding and inactivation, as has been suggested for b2-chimaerin based on structural studies (Canagarajah et al., 2004) . Previous work suggests that chimaerin function can be further regulated by Src-and Cdk5-mediated phosphorylation events, as well as by diacylglycerol generated from PLCb-or PLCg-coupled receptors (Brown et al., 2004; Buttery et al., 2006; Caloca et al., 1999; Canagarajah et al., 2004; Kai et al., 2007; Qi et al., 2004; Wang et al., 2006) . How these different signaling pathways intersect downstream of EphA4 remains to be shown.
Notably, a recent proteomic analysis of an EphB2-overexpressing cell line identified b2-chimaerin in phosphotyrosine-containing protein complexes after EphB2 stimulation (Zhang et al., 2006) . Therefore, b2-chimaerin may also be recruited by Eph-receptor activation. However, our data indicate that neither a1-nor b2-chimaerin isoforms can compensate for the loss of a2-chimaerin in vivo. The severe impairment of EphA4 forward signaling in a2-chimaerin mutant mice suggests that, with respect to other effectors, there is no redundancy in the signaling pathways downstream of EphA4. How can this be explained considering that EphA4 interacts with multiple RhoGTPase GAPs and GEFs? Ablation of ephexin-1 or Vav-2/Vav-3, which couple to activated EphA4 receptors, does not phenocopy the locomotor defects observed in EphA4 and a2-chimaerin mutant mice. Rather, these mutants show defects in retinal ganglion cell axon guidance Sahin et al., 2005) . Therefore, dedicated Eph-receptor effectors might act in a cell-typespecific manner. The significant number of proteins with predicted GAP or GEF domains encoded in mammalian genomes would make such a scenario possible. Alternatively, multiple RhoGTPase regulators might act sequentially within the same cell type. Studies in retinal axons reported ephrin-induced downregulation of Rac activity within minutes followed by an increase of active Rac levels over the next 30 min (Jurney et al., 2002) . Therefore, a2-chimaerin-mediated Rac inactivation might represent an early step in EphA4-mediated responses followed by an increase in active Rac through the RacGEF activity of Vav-2 and/or Vav-3, which might result in Eph-receptor endocytosis and termination of signaling . In this latter scenario, only the first a2-chimaerindependent step would exclusively rely on a single effector protein; whereas, the subsequent steps might be controlled through multiple overlapping pathways. Regardless of the exact mechanism, our data demonstrate that a2-chimaerin is essential for EphA4 signaling in spinal locomotor circuits.
The second important observation in our study is the selectivity of the a2-chimaerin phenotype. Previous studies highlighted axon guidance defects in several central regulators of the cytoskeleton, including the RhoGTPases, PI3-kinase, Abelson kinase, and Ena/VASP family proteins, which are common signaling mediators for multiple neuronal surface receptors (Bashaw et al., 2000; Chang et al., 2006; Lebrand et al., 2004; Ng and Luo, 2004; Wills et al., 1999) . The defects in a2-chimaerin mutant mice appear to be rather selective for EphA4-dependent pathways. Previous work suggested a function for a2-chimaerin in semaphorin/plexin-induced growth responses in cultured DRG neurons (Brown et al., 2004) . We found that plexinA1-dependent central projections of proprioceptive afferents were not perturbed in a2-chimaerin mutants. Therefore, a2-chimaerin is either not involved in plexin signaling in vivo or other Rho regulators, including other chimaerin isoforms, act redundantly with a2-chimaerin in this pathway. Our biochemical studies also suggest an interaction of a2-chimaerin with EphB receptors. This warrants future studies to test whether a2-chimaerin is a dedicated effector for EphA4 or whether it also transduces EphB receptor signaling events in vivo.
EXPERIMENTAL PROCEDURES cDNAs and Recombinant Proteins
Full-length and mutant EphA4 cDNAs were generously provided by Dr. Greenberg. The following recombinant proteins were purified from E. coli and coupled to glutathione sepharose or NHS-activated sepharose beads: glutathione S-transferase (GST); GST-SH2, containing amino acids 1-182 of murine a2-chimaerin; maltose-binding protein (MBP); MBP-A4, containing residues 572-978 (the intracellular domain) of murine EphA4; MBP-A4/KD containing the intracellular domain with a V635M mutation; and MBP-A4/EE containing the intracellular domain with Y596E and Y602E mutations.
Biochemical Assays
Mouse brains from P14 animals were homogenized and separated into cytosol, membrane, and nuclear fractions. The membrane fraction was solubilized in 50 mM HEPES (pH 7.5), 1% triton X-100, 0.5% sodiumdeoxycholate, 10% glycerol, 100 mM NaCl, 1.5 mM MgCl 2 , 1 mM EGTA, 10 mM NaF, 1 mM Na 3 VO 4 , and the solubilized membrane proteins were passed over a column with purified recombinant SH2 domain of a2-chimaerin fused to GST. Proteins were eluted with increasing sodium chloride concentrations (50 mM to 2 M NaCl), and eluted proteins were analyzed by silver staining and western blotting. For the pull-down assays, all cDNA expression vectors used for expression of proteins contained the CMV immediate-early promoter and epitope tags for detection. HEK293T cells were transiently transfected using Fugene (Roche). Sixteen hours after transfection, cells were lysed in 50 mM HEPES (pH 7.5), 0.5% triton X-100, 10% glycerol, 1.5 mM MgCl 2 , 1 mM EGTA, 100 mM NaF, and 1 mM Na 3 VO 4 . Pull-downs with GST-SH2 beads were performed with 150 ml cell or tissue lysate diluted in 450 ml 20 mM HEPES (pH 7.5), 50 mM NaCl, 10% glycerol, 1 mM EGTA, 1.5 mM MgCl 2 , 1 mM NaF, 1 mM Na 3 VO 4 , for 3 hr at 4 C. MBP/MBP-A4/MBP-KD beads were preincubated in ''Kinase Buffer'' (20 mM HEPES [pH 7.5], 50 mM NaCl, 6 mM MgCl 2 , 4 mM MnCl 2 , 0.1 mM Na 3 VO 4 ) or l-phosphatase buffer (NEB) with 100 mM ATP or l-phosphatase. Pull-downs were performed with 150 ml cell lysate diluted in 450 ml ''Kinase-Buffer'' for 3 hr at 4 C. After all pulldowns, the beads were washed three times with 20 mM HEPES, 120 mM NaCl, 0.2% triton X-100, 10% glycerol, 1 mM EGTA, 1.5 mM MgCl 2 , 1 mM NaF, 1 mM Na 3 VO 4 . All pull-downs were performed in the presence of complete protease inhibitor EDTA free (Roche), one tablet per 10 ml. Proteins were resolved on SDS-PAGE gels, transferred to nitrocellulose, and immunoblotted with the indicated antibodies.
Antibodies
Rat monoclonal anti-HA (Roche, clone 3F10), mouse monoclonal antiEphA4 receptor (Zymed, clone 4C8H5), rabbit anti-EphA4 (generously provided by Dr. Pasquale), rabbit anti-TrkA (Santa Cruz), mouse anti phospho-tyrosine (Santa Cruz, PY99), anti a1 and a2-chimaerin (Buttery et al., 2006) , rat anti-CTIP2 (Abcam), goat anti-b-galactosidase (Biogenesis), mouse anti-NeuN (Chemicon), goat anti-parvalbumin (Swant). Secondary antibodies were from Jackson Immuno Research; for IP-western analysis, secondary antibodies specific to the antibody light chains were used to minimize detection of IgG used for immunoprecipitation.
Retrograde Tracing
Mice containing a gene-trap insertion in the a-chimaerin gene were obtained from Lexicon Genetics. EphA4 mutant mice were previously generated and generously provided by Dr. Patrick Charnay (Helmbacher et al., 2000) . Spinal cords of postnatal day 5 mice were dissected by ventral laminectomy in cold L15 media (Mediatech). Spinal neuronal projections to the contralateral side of the cord were retrogradely labeled by applying crystals of rhodamine dextran (3000 MW, Molecular Probes) to a unilateral cut at the L3/L4 transition. The isolated spinal cords were incubated in oxygenated retrograde transport solution (in mM: 137 NaCl, 5 KCl, 2 CaCl 2 , 1 MgCl 2 , 0.2% w/v glucose, 1 NaH 2 PO 4 , 24 NaHCO 3 [pH 7.4]) for 8-12 hr before immersion fixation and sectioning. Labeled spinal cords were fixed in 4% PFA in 13 PBS for 2 hr, and 50 mm serial vibratome sections were collected and mounted in Fluoromount-G (Southern Biotech). Axon labeling in at least four consecutive sections at the L2 level were analyzed for quantification of retrograde labeling.
Corticospinal Tract Tracing
Adult animals were anesthetized with a ketamine/xylazine mix (100/10 mg/kg body weight; i.p.), and the motor cortex was pressure injected with the anterograde tracer biotin dextran amine (10% BDA in 0.1 M PBS; Molecular Probes, 400 nl into four sites covering the forelimb to hindlimb representation in motor cortex). After 10-11 days, the animals received an overdose of ketamine/xylazine and were transcardially perfused with 13 PBS, followed by 4% PFA in 13 PBS. Spinal cords were isolated and postfixed for 2 hr at room temperature followed by overnight immersion in 30% sucrose. Frozen microtome sections of traced brain and spinal cord (50 mm) were collected and incubated overnight with an avidin-biotin-peroxidase complex (Vectastain ABC Elite Kit, 1:100 in PBS) at room temperature. Sections were reacted with diaminobenzidine (DAB), washed, mounted, coverslipped on glass slides, and examined under darkfield optics using a Zeiss Axioimager microscope.
Corticospinal Stimulation and EMG Recording
Cortical stimulation was performed by stereotaxic insertion of paraleen-insulated tungsten microelectrodes (Microprobe Inc.) into hindlimb motor cortex. Using a constant current stimulator, trains of biphasic initially cathodal stimuli (45 ms, 333 Hz, 0.2 ms pulse duration, trains every 2 s) of increasing intensity were applied until a contralateral hindlimb movement was evoked, whereupon we noted the current (threshold) and the presence or absence of an ipsilateral hindlimb response. Multiple stimuli at threshold intensities were applied to ensure reliable threshold measurements. In wild-type, stimuli at multiples of threshold (up to 5 times) were applied to recruit and ipsilateral hindlimb response in addition to a contralateral hindlimb response. We recorded EMG activity using Ni-chrome wires inserted percutaneously into muscle. The hindlimbs were shaved to facilitate muscle identification and to ensure accurate electrode placement. We used conventional amplification and filtration. For this study, we inspected the recorded EMG during the experiment for concordance between the kinematic effect of stimulation and the pattern of EMG activation.
Growth Cone Collapse Assay
Developing motor cortices from P1 mouse pups were dissected in cold L15 media (Cellgro). Cortical explants were plated in medium (Neurobasal, 13 B27 supplement, 1X penicillin/streptomycin/glutamine mix, 1.2 mM MgCl 2 , 35 mM glucose) on MatTek glass bottom plates coated with 100 mg/ml poly D-lysine and 20 mg/ml Laminin (Invitrogen) and placed in a 37 C/5% CO 2 incubator. After 2 days in culture, explant plates were transferred to a 37 C/5% CO 2 environment microscope for time-lapse image analysis. Individual axonal growth cones from the explants were imaged for a total of 45 min with a 633 1.4 NA Zeiss objective. Growth cones were imaged for 15 min before treatment to determine basal growth rates. After 15 min, 250 ml (1 mg/ml of control Fc protein or ephrinA1-Fc fusion protein) was bath applied to explants, and time-lapse imaging proceeded for an additional 30 min. Each growth cone was imaged at 30 s intervals before and after treatment. Growth cone collapse and distance traveled were scored blind toward genotype using Metamorph image analysis software.
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The Supplemental Data for this article can be found online at http:// www.neuron.org/cgi/content/full/55/5/768/DC1/.
